All In Biotech

NDA 021777 · Teva Pharms Intl

Amrix

Cyclobenzaprine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Feb 1, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

23 Phase 3, 6 recruiting

FAERS reports

9,077

5,296 serious, 754 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2026.

Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. Limitations of Use: Cyclobenzaprine hydrochloride extended-release capsules should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride extended-release capsules have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy. Cyclobenzaprine hydrochloride extended-release capsules are a muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. ( 1 ) Limitations of Use: Cyclobenzaprine hydrochloride extended-release capsules should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. ( 1 ) Cyclobenzaprine hydrochloride extended-release capsules have not been found effective in the...

Mechanism: Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Cyclobenzaprine has not been shown to be effective in muscle spasm due to central nervous system disease. In animal models, cyclobenzaprine reduced or abolished skeletal muscle hyperactivity. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle. Such studies show that cyclobenzaprine acts primarily within the central nervous system at the brain stem as opposed to the spinal cord level, although an overlapping action on the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AMRIX · CYCLOBENZAPRINE HYDROCHLORIDE 15MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • AMRIX · CYCLOBENZAPRINE HYDROCHLORIDE 30MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclobenzaprine" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain1,423
  • headache1,112
  • fatigue1,089
  • drug ineffective833
  • off label use749
  • nausea746
  • constipation715
  • back pain657
  • fall635
  • dyspnoea576
  • rheumatoid arthritis555
  • diarrhoea539

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004119
2005123
2006110
200710
200835
2009114
2010119
2011138
2012116
2013188
2014139
2015192
2016292
2017266
2018339
2019353
2020512
2021631
2022928
2023948
20241,159
20251,244
20261,001

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Amrix (Cyclobenzaprine HCl)

2024 spending

$448K

Beneficiaries

33

148 claims

Per beneficiary

$13,576

$55.64 per unit

View as table
YearSpending
2020$1,243,843
2021$844,798
2022$593,872
2023$577,360
2024$448,018

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 69 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.